The 340B Drug Discount Program was created in 1992 to help federally funded clinics and public hospitals that serve a large uninsured population cover the cost of drugs and provide discounts to patients. But the lack of guardrails on the program and failure to define a patient has led to it being abused by hospitals […]
The federal 340B Drug Pricing Program was intended to provide discounts on drugs to patients but the lack of a clear intent and patient definition, along with inadequate oversight, has led to the program being exploited by hospitals and contract pharmacies to generate millions of dollars in profit. The discounts are supposed to be provided […]
This Week in Waste highlights how taxpayer dollars are being wasted and efforts to fight back against this waste.
President Trump’s EO addresses the dual objectives of lowering drug prices while promoting innovation and protecting IP
The Inflation Reduction Act will ultimately raise drug costs and reduce future cures.
Pharmaceutical price controls in President Biden’s budget and the SMART Choices Act will devastate drug development.
Problems in the 340B drug discount program are growing and costs are increasing due as more entities participate in the program.
The healthcare reform juggernaut, arguably the most radical attempt to remake the economy and the nation’s healthcare infrastructure in history, was supposed to have flown through Congress before the August recess with nary a peep. Instead, as Americans have gotten wind of its alarming provisions and exorbitant costs, the plan appears to be fizzling fast in the summer heat.
